An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain

Cancer Immunity

Volumn 8, Issue , 2008, Pages

  Voelter, Verena ^a,f   Pica, Alessia ^b   Laurent, Julien ^b   Rimoldi, Donata ^c   Bouzourene, Hanifa ^b   Sajadi, Ali ^d   Matter, Maurice ^b   Romero, Pedro ^c   Rufer, Nathalie ^b,e   Speiser, Daniel E ^c,e  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^e Nationale Forschungsschwerpunkte NFS   (Switzerland)

^f Celgene International   (Switzerland)

Author keywords

Cellular immunity; Human; Melanoma; Tumor escape

Indexed keywords

ANTINEOPLASTIC AGENT; CD28 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CISPLATIN; DACARBAZINE; IMMUNOLOGIC AGENT; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE;

ADULT; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CD8+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEFT HEMISPHERE; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; TREATMENT OUTCOME;

EID: 41949105576     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
2. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
3. Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-6755.
4. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350: 1461-1463.
5. Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004; 4: 4. URL: http://www.cancerimmunity.org/v4p4/040404.htm
6. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-746.
7. Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/ MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 2006; 177: 6769-6779.
8. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 2003; 63: 5601-5606.
9. Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest 2004; 113: 1225-1233.
10. Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol 2005; 174: 5092-5099.
11. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Lienard D, Cerottini JC, Romero P, Rufer N. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006; 177: 1338-1348.
12. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004; 10: 5316-5326.
13. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878-887.
14. Gabrilovich DI. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 2007; 8: 2-3.